NCT00772382View on ClinicalTrials.gov

Study of MCI-196 in Chronic Kidney Disease Stage V Subjects on Dialysis With Hyperphosphatemia

PHASE3CompletedINTERVENTIONAL
Enrollment

116

Participants

Timeline

Start Date

December 31, 2008

Primary Completion Date

August 31, 2010

Study Completion Date

August 31, 2010

Conditions
Chronic Kidney DiseaseDialysisHyperphosphatemia
Interventions
DRUG

MCI-196

3g to 15g/day (3 times a day), Tablet, 52 weeks of flexible dose

Trial Locations (21)

Unknown

Los Angeles

Orange

Tarzana

Orlando

Pembroke Pines

Atlanta

Gurnee

Evansville

Baton Rouge

New Orleans

Northport

Durham

Oklahoma City

Nashville

Houston

Burlington

Chesapeake

Kamloops

London

Toronto

Montreal

Sponsors
All Listed Sponsors
lead

Mitsubishi Tanabe Pharma Corporation

INDUSTRY